Alexza Pharmaceuticals (ALXA) 4.79 $ALXA
Alexza Provides Pipeline Update
PR Newswire - Thu Jul 31, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on its pipeline and new product development efforts. In the second half of 2014, Alexza expects to initiate a Phase 2a study of AZ-002 (Staccato® alprazolam), which is being developed for the management of patients with acute repetitive seizures. Additionally, Alexza has identified two new Staccato-based product candidates for development - AZ-008 and AZ-009 - which will incorporate the active pharmaceutical ingredient ropinirole, a dopamine agonist, into Alexza's proprietary Staccato system. The Company plans to develop AZ-008 for the acute treatment of restless legs syndrome (RLS) and AZ-009 for hypomobility, or freezing, during "off periods" in Parkinson's disease (PD) patients.
Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences
PR Newswire - Tue Jul 29, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it is participating in two healthcare conferences during the third quarter, the 2014 Avondale Partners Healthcare 1-1 Conference and the Morgan Stanley Global Healthcare 2014 Conference. Alexza's corporate presentation will be webcast live from the Morgan Stanley Conference. The details on each event are below:
Alexza to Report 2014 Second Quarter Financial Results on Thursday, August 7, 2014
PR Newswire - Thu Jul 17, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended June 30, 2014 on Thursday, August 7, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Global Seizures Therapeutics Pipeline Review, H1 2014 - 9 Companies & 12 Drug Profiles
M2 - Tue Jul 01, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ccl3gq/seizures) has announced the addition of the "Seizures - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seizures and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Novartis AG - Acorda Therapeutics, Inc. - Pfizer Inc. - Upsher-Smith Laboratories, Inc. - Concert Pharmaceuticals, Inc. - Advicenne Pharma - Ultragenyx Pharmaceutical Inc. - Sage Therapeutics Drug Profiles - diazepam - midazolam hydrochloride - everolimus - diazepam - UX-007 - topiramate - alprazolam - ADV-6208 - C-10068 - CCG-63802 - Dihydroxyflavone - SAGE-NCE For more information visit http://www.researchandmarkets.com/research/ccl3gq/seizures
Alexza Announces the Promotion of Edwin S. Kamemoto, Ph.D. to Senior Vice President, Regulatory Affairs
PR Newswire - Mon Jun 30, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the promotion of Edwin S. Kamemoto, Ph.D., to the newly created position of Senior Vice President, Regulatory Affairs. Dr. Kamemoto will have primary responsibility for leading and directing all regulatory affairs and global pharmacovigilence activities.
Alexza Pharmaceuticals closes private placement of USD45m non-recourse notes
M2 - Thu Mar 20, 7:57AM CDT
Central nervous system treatment company Alexza Pharmaceuticals (NasdaqGM:ALXA) revealed on Wednesday the completion of a private placement of USD45.0m of non-recourse notes to institutional investors.
Alexza Pharmaceuticals Announces Private Placement of $45 Million of Non-Recourse Notes
PR Newswire - Wed Mar 19, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) (Alexza) announced today that it has closed a private placement to institutional investors of $45.0 million of non-recourse notes (the "Notes"
. The Notes are secured by royalties and potential milestones from U.S. sales of ADASUVE® (loxapine) inhalation powder. Alexza's commercial partner for ADASUVE in the U.S. is Teva Pharmaceuticals USA, Inc.
Alexza Pharmaceuticals and Ferrer Announce the Launch of ADASUVE® (inhalation powder, loxapine) in Romania
PR Newswire - Thu Mar 13, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Ferrer today announced that ADASUVE® inhalation powder, pre-dispensed (loxapine) is now available in Romania. Ferrer is Alexza's commercial partner for ADASUVE in the European Union (EU), Latin America and the Commonwealth of Independent States countries. Ferrer is commercializing the product in Romania through a distribution agreement with Galenica, S.A.
Alexza Reports Fourth Quarter and Year End 2013 Financial Results
PR Newswire - Thu Mar 06, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter and year ended December 31, 2013. The net loss for the fourth quarter was $5.7 million compared to $10.3 million during the same quarter in 2012. The net loss for the years ended December 31, 2013 and 2012 was $39.6 million and $28.0 million, respectively. At December 31, 2013, Alexza had consolidated cash, cash equivalents and marketable securities of $25.9 million.
Teva Launches ADASUVE(R) in U.S.
Business Wire - Mon Mar 03, 7:15AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today the commercial launch of ADASUVE(R) (loxapine) inhalation powder 10 mg, the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Alexza Announces the U.S. Commercial Launch of ADASUVE® by Teva Pharmaceuticals
PR Newswire - Mon Mar 03, 7:07AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the U.S. commercial launch of ADASUVE® (loxapine) inhalation powder 10mg by its commercial partner, Teva Pharmaceutical Industries Ltd., (NYSE: TEVA). ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Robert A. Lippe Joins Alexza Pharmaceuticals as Executive Vice President, Operations and Chief Operations Officer
PR Newswire - Tue Feb 25, 8:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Robert A. Lippe has joined the Company as Executive Vice President, Operations and Chief Operations Officer. In this newly created position, Mr. Lippe has responsibility for the Company's global operation functions, including strategic development and execution of clinical and commercial manufacturing, quality and compliance, supply chain and supply partner management, technology transfer, facilities, sustainment engineering and IT in support of the Company's product and technology portfolio.
Alexza Pharmaceuticals' Corporate Presentation to be Webcast from Two Upcoming March Investor Conferences
PR Newswire - Thu Feb 20, 4:00PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today its corporate presentation will be webcast live from two upcoming investor conferences. The webcast of each presentation may be accessed from the Investor Relations section of the Alexza Pharmaceuticals website at www.alexza.com. The conferences and presentation times are:
Alexza to Report 2013 Year-End Financial Results on Thursday, March 6, 2014
PR Newswire - Thu Feb 13, 8:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal year ended December 31, 2013 on Thursday, March 6, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.
Alexza Pharmaceuticals Inc reports availability of ADASUVE in Spain through Grupo Ferrer Internacional SA
M2 - Wed Jan 22, 4:27AM CST
Pharmaceutical company Alexza Pharmaceuticals Inc (NasdaqGM:ALXA) reported on Tuesday the launch of ADASUVE inhalation powder, pre-dispensed in Spain through Grupo Ferrer Internacional SA.
Alexza Pharmaceuticals Announces Ferrer's Launch of ADASUVE® (Staccato® Loxapine) in Spain Triggering a $1 Million Milestone Payment
PR Newswire - Tue Jan 21, 8:05AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that ADASUVE® inhalation powder, pre-dispensed (Staccato® loxapine) is now available in Spain through Grupo Ferrer Internacional, S.A. (Ferrer). Ferrer is Alexza's commercial partner for ADASUVE in the European Union (EU), Latin America, Russia and the CIS countries. In conjunction with this commercial introduction of ADASUVE in Spain by Ferrer, Alexza will receive a milestone payment of $1 million.
Alexza Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
PR Newswire - Thu Aug 29, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the Company will participate in the Stifel Healthcare Conference 2013, being held in Boston, MA, September 11 - 12, 2013. James V. Cassella, PhD, Alexza Executive Vice President and Chief Scientific Officer, will present at the conference. The Alexza corporate presentation will be Wednesday, September 11, 2013 at 9:10 a.m. Eastern Time. The presentation will be webcast live.
Edison expands North American healthcare sector coverage with initiation of coverage on Alexza Pharmaceuticals
PR Newswire - Wed Aug 28, 10:18AM CDT
Edison has recently published a comprehensive report examining the investment merits of Alexza Pharmaceuticals, which are largely based on the company's lead asset, Adasuve (Staccato loxapine), approved in the US and the EU for the acute treatment of agitation in adults with bipolar disorder or schizophrenia. In the report, All eyes on Adasuve, Edison healthcare analyst, Pooya Hemami, argues that Alexza's investment case is underpinned by Adasuve's ability to provide a rapid therapeutic response in a non-invasive formulation, offering a unique treatment option that does not require physicians to trade off either speed of effect or non-coercive dosing. Given the risk of physical injury or property damage with agitated patients in whom agitation is escalating, and that competing treatment options are either slow to act or invasive, Edison believes the advantages of quick effect and ease of administration will position Adasuve as a key agent for the initial treatment of acute agitation in medical emergency settings. Based on a risk-adjusted NPV analysis, Edison values Alexza at $85m, or $6.77 per share (fully diluted) inclusive of $32m in cash (30 June 2013).
Alexza Pharmaceuticals Down 7.5%, Shares Slide into the Red (ALXA)
Comtex SmarTrend(R) - Fri Aug 09, 10:16AM CDT
Alexza Pharmaceuticals (NASDAQ:ALXA) is one of today's worst performing low-priced stocks, down 7.5% to $4.81 on 1.6x average daily volume. Thus far today, Alexza Pharmaceuticals has traded 378,000 shares, vs. average volume of 241,000 shares per day. The stock has underperformed the Dow (-7.5% to the Dow's -0.7%) and underperformed the S&P 500 (-7.5% to the S&P's -0.4%) during today's trading.
Alexza Provides Pipeline Update
PR Newswire - Thu Jul 31, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on its pipeline and new product development efforts. In the second half of 2014, Alexza expects to initiate a Phase 2a study of AZ-002 (Staccato® alprazolam), which is being developed for the management of patients with acute repetitive seizures. Additionally, Alexza has identified two new Staccato-based product candidates for development - AZ-008 and AZ-009 - which will incorporate the active pharmaceutical ingredient ropinirole, a dopamine agonist, into Alexza's proprietary Staccato system. The Company plans to develop AZ-008 for the acute treatment of restless legs syndrome (RLS) and AZ-009 for hypomobility, or freezing, during "off periods" in Parkinson's disease (PD) patients.
Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences
PR Newswire - Tue Jul 29, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it is participating in two healthcare conferences during the third quarter, the 2014 Avondale Partners Healthcare 1-1 Conference and the Morgan Stanley Global Healthcare 2014 Conference. Alexza's corporate presentation will be webcast live from the Morgan Stanley Conference. The details on each event are below:
Alexza to Report 2014 Second Quarter Financial Results on Thursday, August 7, 2014
PR Newswire - Thu Jul 17, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended June 30, 2014 on Thursday, August 7, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Global Seizures Therapeutics Pipeline Review, H1 2014 - 9 Companies & 12 Drug Profiles
M2 - Tue Jul 01, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ccl3gq/seizures) has announced the addition of the "Seizures - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seizures and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Novartis AG - Acorda Therapeutics, Inc. - Pfizer Inc. - Upsher-Smith Laboratories, Inc. - Concert Pharmaceuticals, Inc. - Advicenne Pharma - Ultragenyx Pharmaceutical Inc. - Sage Therapeutics Drug Profiles - diazepam - midazolam hydrochloride - everolimus - diazepam - UX-007 - topiramate - alprazolam - ADV-6208 - C-10068 - CCG-63802 - Dihydroxyflavone - SAGE-NCE For more information visit http://www.researchandmarkets.com/research/ccl3gq/seizures
Alexza Announces the Promotion of Edwin S. Kamemoto, Ph.D. to Senior Vice President, Regulatory Affairs
PR Newswire - Mon Jun 30, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the promotion of Edwin S. Kamemoto, Ph.D., to the newly created position of Senior Vice President, Regulatory Affairs. Dr. Kamemoto will have primary responsibility for leading and directing all regulatory affairs and global pharmacovigilence activities.
Alexza Pharmaceuticals closes private placement of USD45m non-recourse notes
M2 - Thu Mar 20, 7:57AM CDT
Central nervous system treatment company Alexza Pharmaceuticals (NasdaqGM:ALXA) revealed on Wednesday the completion of a private placement of USD45.0m of non-recourse notes to institutional investors.
Alexza Pharmaceuticals Announces Private Placement of $45 Million of Non-Recourse Notes
PR Newswire - Wed Mar 19, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) (Alexza) announced today that it has closed a private placement to institutional investors of $45.0 million of non-recourse notes (the "Notes"
. The Notes are secured by royalties and potential milestones from U.S. sales of ADASUVE® (loxapine) inhalation powder. Alexza's commercial partner for ADASUVE in the U.S. is Teva Pharmaceuticals USA, Inc. Alexza Pharmaceuticals and Ferrer Announce the Launch of ADASUVE® (inhalation powder, loxapine) in Romania
PR Newswire - Thu Mar 13, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Ferrer today announced that ADASUVE® inhalation powder, pre-dispensed (loxapine) is now available in Romania. Ferrer is Alexza's commercial partner for ADASUVE in the European Union (EU), Latin America and the Commonwealth of Independent States countries. Ferrer is commercializing the product in Romania through a distribution agreement with Galenica, S.A.
Alexza Reports Fourth Quarter and Year End 2013 Financial Results
PR Newswire - Thu Mar 06, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter and year ended December 31, 2013. The net loss for the fourth quarter was $5.7 million compared to $10.3 million during the same quarter in 2012. The net loss for the years ended December 31, 2013 and 2012 was $39.6 million and $28.0 million, respectively. At December 31, 2013, Alexza had consolidated cash, cash equivalents and marketable securities of $25.9 million.
Teva Launches ADASUVE(R) in U.S.
Business Wire - Mon Mar 03, 7:15AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today the commercial launch of ADASUVE(R) (loxapine) inhalation powder 10 mg, the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Alexza Announces the U.S. Commercial Launch of ADASUVE® by Teva Pharmaceuticals
PR Newswire - Mon Mar 03, 7:07AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the U.S. commercial launch of ADASUVE® (loxapine) inhalation powder 10mg by its commercial partner, Teva Pharmaceutical Industries Ltd., (NYSE: TEVA). ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Robert A. Lippe Joins Alexza Pharmaceuticals as Executive Vice President, Operations and Chief Operations Officer
PR Newswire - Tue Feb 25, 8:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Robert A. Lippe has joined the Company as Executive Vice President, Operations and Chief Operations Officer. In this newly created position, Mr. Lippe has responsibility for the Company's global operation functions, including strategic development and execution of clinical and commercial manufacturing, quality and compliance, supply chain and supply partner management, technology transfer, facilities, sustainment engineering and IT in support of the Company's product and technology portfolio.
Alexza Pharmaceuticals' Corporate Presentation to be Webcast from Two Upcoming March Investor Conferences
PR Newswire - Thu Feb 20, 4:00PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today its corporate presentation will be webcast live from two upcoming investor conferences. The webcast of each presentation may be accessed from the Investor Relations section of the Alexza Pharmaceuticals website at www.alexza.com. The conferences and presentation times are:
Alexza to Report 2013 Year-End Financial Results on Thursday, March 6, 2014
PR Newswire - Thu Feb 13, 8:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal year ended December 31, 2013 on Thursday, March 6, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.
Alexza Pharmaceuticals Inc reports availability of ADASUVE in Spain through Grupo Ferrer Internacional SA
M2 - Wed Jan 22, 4:27AM CST
Pharmaceutical company Alexza Pharmaceuticals Inc (NasdaqGM:ALXA) reported on Tuesday the launch of ADASUVE inhalation powder, pre-dispensed in Spain through Grupo Ferrer Internacional SA.
Alexza Pharmaceuticals Announces Ferrer's Launch of ADASUVE® (Staccato® Loxapine) in Spain Triggering a $1 Million Milestone Payment
PR Newswire - Tue Jan 21, 8:05AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that ADASUVE® inhalation powder, pre-dispensed (Staccato® loxapine) is now available in Spain through Grupo Ferrer Internacional, S.A. (Ferrer). Ferrer is Alexza's commercial partner for ADASUVE in the European Union (EU), Latin America, Russia and the CIS countries. In conjunction with this commercial introduction of ADASUVE in Spain by Ferrer, Alexza will receive a milestone payment of $1 million.
Alexza Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
PR Newswire - Thu Aug 29, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the Company will participate in the Stifel Healthcare Conference 2013, being held in Boston, MA, September 11 - 12, 2013. James V. Cassella, PhD, Alexza Executive Vice President and Chief Scientific Officer, will present at the conference. The Alexza corporate presentation will be Wednesday, September 11, 2013 at 9:10 a.m. Eastern Time. The presentation will be webcast live.
Edison expands North American healthcare sector coverage with initiation of coverage on Alexza Pharmaceuticals
PR Newswire - Wed Aug 28, 10:18AM CDT
Edison has recently published a comprehensive report examining the investment merits of Alexza Pharmaceuticals, which are largely based on the company's lead asset, Adasuve (Staccato loxapine), approved in the US and the EU for the acute treatment of agitation in adults with bipolar disorder or schizophrenia. In the report, All eyes on Adasuve, Edison healthcare analyst, Pooya Hemami, argues that Alexza's investment case is underpinned by Adasuve's ability to provide a rapid therapeutic response in a non-invasive formulation, offering a unique treatment option that does not require physicians to trade off either speed of effect or non-coercive dosing. Given the risk of physical injury or property damage with agitated patients in whom agitation is escalating, and that competing treatment options are either slow to act or invasive, Edison believes the advantages of quick effect and ease of administration will position Adasuve as a key agent for the initial treatment of acute agitation in medical emergency settings. Based on a risk-adjusted NPV analysis, Edison values Alexza at $85m, or $6.77 per share (fully diluted) inclusive of $32m in cash (30 June 2013).
Alexza Pharmaceuticals Down 7.5%, Shares Slide into the Red (ALXA)
Comtex SmarTrend(R) - Fri Aug 09, 10:16AM CDT
Alexza Pharmaceuticals (NASDAQ:ALXA) is one of today's worst performing low-priced stocks, down 7.5% to $4.81 on 1.6x average daily volume. Thus far today, Alexza Pharmaceuticals has traded 378,000 shares, vs. average volume of 241,000 shares per day. The stock has underperformed the Dow (-7.5% to the Dow's -0.7%) and underperformed the S&P 500 (-7.5% to the S&P's -0.4%) during today's trading.
